CLINICAL STUDIES OF BRL 28500 (CLAVULANIC ACID-TICARCILLIN)
スポンサーリンク
概要
- 論文の詳細を見る
BRL 28500, a new formulation of the antibiotic ticarcillin (15 parts) with the βlactamase inhibitorclavulanic acid (1 part), was intravenously administrated to 11 patients with respiratory tract infection, one with a subcutaneous abscess and 2 with fever of unknown origin. The patients received the drug for between 3 and 25 days at doses of 3.2-9.6g/day.<BR>Clinical effects were excellent in 2 cases, good in 6, poor in 3 and unassessable in 3. The efficacy rate was thus 72. 7%(8/11).<BR>Regarding side effects, rash was observed in one patient. No abnormal laboratory findings related to treatment were observed.
- 公益社団法人 日本化学療法学会の論文
公益社団法人 日本化学療法学会 | 論文
- DISPOSITION OF 7432-8 IN RATS (I)
- CLINICAL STUDIES ON T-1220 IN SURGICAL CASES
- CLINICAL STUDIES OF PIVALOYLOXYMETHYL D-α-AMINOBENZYL-PENICILLINATE HYDROCHLORIDE IN SURGICAL INFECTIONS
- STUDIES ON AC-1370
- Primary treatment with a combination of cyclophosphamide, vincristine, and dacarbazine for recurrent malignant pheochromocytoma: A case report.